Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA has approved Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy. Avmapki Fakzynja Co-Pack is the first and only FDA-approved medicine for this disease.

May 23, 2025

Vol.51 No.20

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

AbbVie announced the final analysis of the confirmatory phase III MIRASOL trial evaluating the efficacy and safety of Elahere in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels.

March 21, 2025

Vol.51 No.11

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

YOU MAY BE INTERESTED IN

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Renew today!

Subscriber content

Never miss an issue!

Login